A checklist for FDA pre-application conference preparation

Preparing for a Pre-Application Conference (PAC) is a critical step in the drug development lifecycle, serving as a unique opportunity to align your scientific data and regulatory strategy with the agency before formal submission. This session allows sponsors to present their program's most important questions and receive guidance from FDA staff, ensuring that the eventual New Drug Application (NDA) or Biologics License Application (BLA) meets all regulatory expectations and avoids costly delays.

Defining the Scope and Objectives

The first phase of preparation involves a rigorous internal review to determine exactly what information the FDA needs to evaluate. Sponsors must clearly define the scope of the meeting, ensuring that the agenda focuses on high-impact issues rather than general overview discussions. It is essential to identify the specific regulatory questions that could significantly influence the design of the clinical trials or the characterization of the investigational product. By narrowing the focus, you ensure that the meeting remains productive and that the FDA staff can provide actionable insights rather than generic advice.

Assembling the Right Team

Selecting the right attendees is just as important as defining the agenda. The team leading the PAC should include a combination of regulatory affairs experts, clinical scientists, and formulation specialists who possess deep knowledge of the specific disease area and the drug's unique properties. Having a dedicated speaker who can articulate the scientific rationale clearly is vital, while regulatory experts ensure that the discussion adheres to current guidelines. Furthermore, having a designated note-taker or liaison on-site is highly recommended to capture the agency's feedback in real-time, creating a comprehensive record of the guidance provided.

Developing a Comprehensive Question List

One of the most common pitfalls in PAC preparation is submitting too many vague questions or failing to prioritize them effectively. The preparation process must involve compiling a list of questions that are specific, well-researched, and directly tied to the data already generated. These questions should address critical uncertainties regarding study design, statistical analysis plans, or specific safety concerns. Before the meeting, the team should review recent FDA guidance documents and similar advisory committee meetings to ensure that the questions are novel and not already covered by existing resources. This diligence demonstrates respect for the agency's workload and increases the likelihood of receiving a substantive response.

Reviewing Relevant Guidance and Standards

Thoroughly studying the most recent FDA guidance documents, policy statements, and previous advisory committee meeting minutes is a mandatory prerequisite for PAC attendance. Understanding the current landscape of the regulatory environment allows you to frame your questions in a way that resonates with the agency's priorities. You should also review the specific requirements for the therapeutic class of your drug, such as those found in the 21 CFR Part 312 for investigational new drugs or specific industry-specific guidance. By pre-reading these materials, you can identify potential gaps in your current strategy and formulate targeted inquiries that require the FDA's expertise.

Simulating the Meeting Dynamics

Finally, conducting a mock meeting or table-top exercise with your internal team can simulate the pressure and dynamics of a real PAC. This exercise helps the team practice presenting data concisely, anticipating potential challenges from FDA reviewers, and understanding how to respond to feedback during the session. It also provides a chance to refine the presentation materials, ensuring they are clear, visually compelling, and free of ambiguity. Practicing these scenarios allows the team to build confidence and ensures that everyone is on the same page regarding the expected outcome of the conference.

By following these structured steps, sponsors can maximize the value of their Pre-Application Conference, turning a routine regulatory check-in into a strategic advantage that accelerates the path to market approval. To ensure absolute clarity during the interaction, the team must adhere to a specific checklist of deliverables and behaviors:

  1. Prepare a concise, visually driven presentation that strictly adheres to the time limits set by the conference.
  2. Have a pre-approved script for all verbal responses to ensure consistent messaging and avoid improvisation errors.
  3. Confirm the specific meeting location and access protocols for the FDA staff and any invited guests.
  4. Distribute all necessary background data packets to the regulatory affairs team at least 48 hours prior to the session.
  5. Establish a clear post-meeting follow-up plan to document agreed-upon next steps and timelines for submission.
  6. Ensure all team members understand the specific role of the liaison during the Q&A session to facilitate smooth flow.
  7. Review the internal risk register to anticipate any potential regulatory hurdles that might be raised by agency reviewers.

Related reading